(Q44738673)

5 December 2017

title

Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation (English)

1 reference

5 December 2017

0 references

1 reference

1 reference

Ye Song

1

1 reference

5 December 2017

Cai Li

series ordinal

2

1 reference

5 December 2017

Lu Cai

series ordinal

3

1 reference

5 December 2017

publication date

1 February 2004

1 reference

Experimental and Molecular Pathology

5 December 2017

published in

1 reference

5 December 2017

volume

76

1 reference

5 December 2017

issue

1

1 reference

5 December 2017

page(s)

66-75

1 reference

Can glomerular mRNAs in human type 1 diabetes be used to predict transition from normoalbuminuria to microalbuminuria?

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

The transforming growth factor beta system in kidney disease and repair: recent progress and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

7 January 2021

Diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Effects of dietary protein on renal function and lipid metabolism in five-sixths nephrectomized rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Fluvastatin: effects beyond cholesterol lowering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Delayed wound healing in immunodeficient TGF-beta 1 knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Mesangial matrix modulation and glomerulosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Antioxidative effects of fluvastatin and its metabolites against DNA damage in streptozotocin-treated mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Effects of the new hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on anti-oxidant enzyme activities and renal function in streptozotocin-induced diabetic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Dysregulation of IFN-gamma signaling pathways in the absence of TGF-beta 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Direct inhibitory effects of simvastatin on matrix accumulation in cultured murine mesangial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Determination of matrix metalloproteinase activity using biotinylated gelatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Connective tissue growth factor and its regulation: a new element in diabetic glomerulosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

TGF-beta in diabetic kidney disease: role of novel signaling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Diabetes enhances lipopolysaccharide-induced cardiac toxicity in the mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2003.08.002

10.1016/J.YEXMP.2003.08.002

7 January 2021

Identifiers

DOI

1 reference

5 December 2017

1 reference